Exxel Pharma is a privately held pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. The Company’s lead program, EX937, is an oral, innovative, proprietary small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel plans to launch a first-in-human Phase 1/1b study of EX937 for the treatment of refractory chronic cough, a large underserved market with no current FDA-approved therapies. In preclinical studies, EX937 was found to be effective in multiple models of chronic cough. Additionally, EX937 has a favorable safety profile and, being entirely excluded from the brain, has negligible central side effect liability. EX937 also has the potential to be utilized across a number of high-value indications, including migraine headache, painful peripheral neuropathies (e.g., caused by cancer chemotherapy) and hyperactive bladder. In addition to EX937, Exxel Pharma is advancing a second program focused on novel global FAAH inhibitors and targeting Social Anxiety and Autism Spectrum Disorder.

These globally active FAAH inhibitors leverage a chemical scaffold similar to EX937 to achieve body-wide enhancement of anandamide-mediated signaling. Substantial preclinical and clinical data with these and other FAAH inhibitors indicate potential usefulness in the treatment of Social Anxiety Disorder and Autism Spectrum Disorder.